Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Last Updated: Friday, July 17, 2026

A retrospective review that examines the clinical characteristics, bone marrow findings, engraftment, and hematopoietic reconstitution of patients who received a stem cell transplantation for a CAR T-cell therapy-related hematologic toxicity, such as cytopenia and sepsis.

Blood Advances

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study

Frontiers in Oncology

Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

CAR T-Cell Therapy Resource Center

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.

Frontiers in Immunotherapy

Smart control of CAR-T cells: Emerging strategies for safer and more effective cancer immunotherapy

Molecular Therapy

CDK4/6 inhibition enhances CAR-T cell therapy in solid tumors

Nature Medicine

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: A phase 1 study

Frontiers in Oncology

Safety and efficacy of CAR T-cell therapy in central nervous system lymphoma: A systematic review and meta-analysis

Journal of Translational Medicine

Asiaticoside enhances the antitumor efficacy of MSLN-targeted CAR-T cells in ovarian cancer

Trends in Cancer

In vivo CAR T cell engineering: Design principles and open questions

Blood Cancer Discovery

Multiomic and longitudinal dissection of immune dynamics associated with parkinsonism after ciltacabtagene autoleucel therapy

Blood Advances

Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

Molecular Immunology

Navigating the frontier of CAR-T cell resistance: From underlying mechanisms to innovative therapeutic solutions

Cancer

Second-line chimeric antigen receptor T-cell therapy versus standard of care in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis

Identifying and Managing CAR T-Associated Hemophagocytic Lymphohistiocytosis Following Dual-Targeted CAR T-Cell Therapy

Prophylactic Tocilizumab in Selected High-Risk or Outpatient CAR-T Populations

Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy in a Patient With Multiple Myeloma

Fast Facts #12: BCMA Targets